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Abstract
Myostatin is a TGFb family member and negative regulator of muscle size. Due to the complexity of the molecular pathway
between myostatin mRNA/protein and changes in transcription, it has been difficult to understand whether myostatin plays
a role in resistance exercise-induced skeletal muscle hypertrophy. To circumvent this problem, we determined the
expression of a unique myostatin target gene, Mighty, following resistance exercise. Mighty mRNA increased by 6 h
(82.9624.21%) and remained high out to 48 h (56.5619.67%) after resistance exercise. Further examination of the soleus,
plantaris and tibialis anterior muscles showed that the change in Mighty mRNA at 6 h correlated with the increase in muscle
size associated with this protocol (R2 = 0.9996). The increase in Mighty mRNA occurred both independent of Smad2
phosphorylation and in spite of an increase in myostatin mRNA (341.86147.14% at 3 h). The myostatin inhibitor SKI
remained unchanged. However, activated Notch, another potential inhibitor of TGFb signaling, increased immediately
following resistance exercise (83611.2%) and stayed elevated out to 6 h (78616.6%). Electroportion of the Notch
intracellular domain into the tibialis anterior resulted in an increase in Mighty mRNA (63613.4%) that was equivalent to the
canonical Notch target HES-1 (94.467.32%). These data suggest that acute resistance exercise decreases myostatin signaling
through the activation of the TGFb inhibitor Notch resulting in a decrease in myostatin transcriptional activity that
correlates well with muscle hypertrophy.
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Introduction
Myostatin, or growth and differentiation factor (GDF-8), is a
member of the transforming growth factor (TGF) b superfamily of
proteins. Canonically, myostatin association with the activin IIB
receptor (ActRIIB) increases Smad2/3-mediated transcription and
represses muscle growth [1]. Interfering with the myostatin
pathway at any point leads to an increase in muscle size through
a poorly understood mechanism. Substantial hypertrophy occurs
when myostatin is decreased genetically [2], immunologically
using myostatin-specific antibodies [3] and by interfering with the
activation of the activin IIB receptor (ActRIIB) either with the
myostatin propeptide or the circulating inhibitor follistatin
[1,4,5,6]. Additionally, impairing downstream myostatin signaling
by increasing SKI, a repressor of Smads, also induces substantial
hypertrophy [7,8]. The fact that so many constituents of this
pathway can induce muscle hypertrophy suggests myostatin plays
a central role in the regulation of muscle mass by resistance
exercise. However, due to the complexity of measuring myostatin
activity, this relationship remains unclear.
Even though evidence exists that myostatin is transcriptionally
downregulated by resistance exercise [9,10], there is no correlation
between the downregulation of myostatin and muscle growth [11].
This is in stark contrast to components of the mTORC1 pathway
that show a tight correlation between their activation following
resistance exercise and increases in muscle mass and strength
following training [12,13]. However, only limited evidence using a
small number of biomarkers of myostatin activity in response to
resistance training exists [14]. Additionaly, when analyzing the
potential importance of myostatin signaling in response to
resistance exercise no one has effectively measured all of the
different aspects of the pathway (i.e. myostatin, propeptide,
follistatin, SKI/Sno, etc.) simultaneously to get a true measure
of myostatin activity. Marshall et al. [15] have described a direct
transcriptional target of myostatin termed Mighty that might aide
in the characterization of myostatin activation following resistance
exercise. Mighty expression is decreased by myostatin in a dose-
dependent manner [15]. Interestingly, an increase in Mighty
mRNA precedes that of MyoD during differentiation and
overexpression of Mighty promotes differentiation in C2C12
muscle cells [15]. Furthermore, Mighty has recently been
identified as a potential regulator of satellite cell chemotaxis
during muscle regeneration [16]. Together, these data suggest that
Mighty is a key developmental mediator of the growth effects of
myostatin.
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The effect of Mighty on satellite cell function and muscle
regeneration is reminiscent of the interplay between TGFb and
Notch signaling [17]. In the satellite cells of older individuals, there
is an increase in TGFb/Smad pathway and a decrease in Notch
signaling [18]. Activating Notch signaling in these cells resulted in
the downregulation of cyclin-dependent kinase inhibitors concom-
itant with a decrease in the activity of TGFbeta as measured by
Smad transcriptional activity [18]; this suggests that Notch can
functionally inhibit TGFb signaling and promote satellite cell
proliferation. Furthermore, loading increases Notch activity [19],
and an increase in the Notch family member delta-like 1 (DLK1) is
responsible for the hypertrophic phenotype in the callipyge sheep
[20]. Together, these data suggest that Notch may be involved in
the regulation of myostatin/TGFb signaling and skeletal muscle
mass.
Notch activation is a complex process involving proteolytic
cleavage of this single pass transmembrane receptor resulting in
the production of the soluble Notch Intracellular Domain (NICD).
NICD translocates to the nucleus where it can interact with
transcription factors such as CSL (CBF-1, supressor of hairless,
lag2) to create a transcriptional activation complex to increase the
transcription of Notch target genes such as Hes-1 [21] or inhibit
the expression of genes regulated by TGFb [18] or activator
protein-1 [22]. Since Mighty is a direct transcriptional target of
myostatin, we hypothesized that the expression of Mighty mRNA
could be used as a tool for determining the overall activity of the
myostatin pathway in skeletal muscle following resistance exercise
and in response to changes in Notch activity. The finding that
Mighty expression increased in proportion to muscle growth led us
to investigate the canonical myostatin signaling pathway and the
activity of Notch in an attempt to understand how myostatin
transcription is regulated following acute resistance exercise. Our
data suggest that activation of Notch, as measured by the increase
in NCID levels following loading, leads to repression of the
myostatin pathway leading to increased Mighty expression. Materials and Methods
Materials
The antibodies used in the study were: rabbit anti-phospho-
Smad2 (#3108) and rabbit anti-GAPDH (#5174 lot#3) from
Figure 1. Mighty expression in TA muscle following resistance
exercise. The expression of Mighty was determined at the end of a
20 min bout of high force lengthening contractions and then 0.5, 3, 6,
18, and 48 hours later. Mighty mRNA increased following resistance
exercise starting at 6 h. *indicates significantly greater than the
contralateral control leg (n = 4, p,0.05).
doi:10.1371/journal.pone.0068743.g001
Figure 2. Correlation between average Mighty mRNA expres-
sion in 3 different muscles 6 hours after stimulation and
average hypertrophy after 6 weeks of training. Since the
expression of Mighty increased 6 h following an acute bout of
resistance exercise in the TA muscle, Mighty expression was determined
in the soleus (SOL) and plantaris (PLN) muscles as well. Mighty mRNA at
6 h was plotted against data on the increase in muscle mass following 6
weeks of repeated bouts of resistance exercise from a previous study
using this model [12]. There was a significant correlation between the
mean difference in Mighty mRNA in each muscle at 6 h and the mean
difference in muscle mass following 6 weeks of training (R2 = 0.9996).
doi:10.1371/journal.pone.0068743.g002
Figure 3. Canonical myostatin signaling following resistance
exercise. The expression of genes within the myostatin pathway was
determined in TA muscle at the end of a 20 min bout of high force
lengthening contractions and then 0.5, 3, 6, 18, and 48 hours later.
Myostatin and follistatin mRNA increased following resistance exercise
starting at 3 h. The expression of the myostatin receptor (ActRIIB) was
unchanged at any time point. *indicates significantly greater than the
contralateral control leg for follistatin and { indicates significantly
greater than the contralateral control leg for myostatin (n = 4, p,0.05).
doi:10.1371/journal.pone.0068743.g003
Mighty and Resistance Exercise
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Cell Signaling (Beverly, MA); total-Smad2/3
(#3862 lot#0509010605) from Chemicon (Billerica, MA); rabbit
anti- Notch intracellular domain (#8925 lot#888593) from
Abcam (Cambridge, MA); and mouse anti-SKI
(#33693 lot#3007) from Santa Cruz Biotechnologies (Santa
Cruz, CA). All other chemicals were from Sigma-Aldrich unless
stated otherwise.
Animals and Acute Resistance Exercise
All procedures were approved by the University of Dundee
research ethics committee and performed under UK Home Office
project license number 60/3441. Adult female Wistar rats
weighing ,200 g were obtained from Charles River Laboratories
(Tranent, UK). All surgical and collection procedures on animals
took place under inhaled anaesthetic using a 2.5% concentration
of isoflurane throughout the procedure. The resistance exercise
model was performed as described previously [12]. Briefly, the
stimulation protocol consisted of two second tetanic contractions
followed by 10 s recovery. After the sixth repetition a 1 min
recovery was allowed. The protocol finished after the 10th set and
then immediately or 0.5, 3, 6, 18, and 48 hours following the acute
bout of contractions, stimulated and contralateral muscles were
rapidly removed, snap frozen in liquid nitrogen and stored at
280uC until processed.
mRNA Extraction
mRNA was extracted from powdered muscles following
homogenization in 1 mL of Trizol. The homogenate was
centrifuged at 4uC for 10 minutes at 11000 rpm to remove
insoluble material and RNA was then precipitated using chloro-
form separation, followed by isopropanol precipitation of the
aqueous layer. RNA was quantified using a NanoDrop 1000
spectrophotometer (Thermo Scientific, Leicestershire, UK) at 260
and 280 nm.
Reverse Transcription and qPCR
First strand cDNA was synthesized from 1 mg of RNA using the
reverse transcription system (Promega, Hampshire, UK). RNA
was denatured with oligo (DT) primers at 70uC for 10 minutes and
the reverse transcription reaction was performed at 50uC for
1 hour. cDNA was diluted 1:10 before use in qPCR.
qPCR was performed using an Eppendorf Mastercycler ep Real
Time Thermocycler (Eppendorf) along with a SYBR Green Jump
Start Taq ready mix (Sigma) and 96 well plates (Fisher). PCR
reactions were performed according to manufacturer’s instructions
with primers (sequence available at FMBlab.com) used at a
concentration of 10 pM. PCR conditions were as follows: initial
denaturation at 95uC for 15 minutes followed by 40 cycles of
denaturation at 94uC for 15 seconds, annealing at 56uC for 30
seconds and extension at 72uC for 30 seconds. A melt curve was
then performed to assess the specificity of the primers and the
PCR product was run on a 1% agarose gel to check product
purity. PCR efficiencies were also determined for each primer set.
The ratio of expression of the gene of interest normalized against
GAPDH was computed according to the equation proposed by
Pfaffl [23].
Correlation between Mighty and Growth
A correlation between the increase in Mighty mRNA 6 hours
following resistance exercise and the growth of muscle following 6
weeks of training was performed by comparing the mean increase
in Mighty mRNA in the current study to our historical data on
muscle growth following stimulation two days per week for 6 weeks
[12]. To facilitate the comparison, the current study used the
identical stimulation model as well as rats of the same strain, age,
and body weight.
Western Blotting
Muscles were powdered on dry ice using a mortar and pestle
and polytron homogenized in 10-fold mass excess of ice cold
sucrose lysis buffer (50 mM Tris pH7.5, 250 mM Sucrose, 1 mM
Figure 4. Smad2 phosphorylation following resistance exercise. The degree of Smad2 phosphorylation was determined in an attempt to
measure myostatin signaling in vivo at the end of a 20 min bout of high force lengthening contractions and then 0.5, 3, 6, 18, and 48 hours later.
Smad2 phosphorylation was unchanged at any time point following resistance exercise (n = 4).
doi:10.1371/journal.pone.0068743.g004
Mighty and Resistance Exercise
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EDTA, 1 mM EGTA, 1% Triton X 100, 50 mM NaF, 1 mM
NaVO4 Na2(PO4)2 and 0.1% DTT). This was vortexed for 30
minutes at 4uC and centrifuged at 4uC for 10 minutes at 10,0006g
to remove insoluble material. Protein concentrations were
determined using the DC protein assay (Bio-Rad, Hercules;
California, USA).
Equal aliquots of protein were diluted in Laemmli sample buffer
and boiled for 5 minutes. 5–10 mg of sample was then subjected to
SDS-PAGE on 10% acrylamide gels at a constant current equal to
20 mA per gel and transferred to Protran nitrocellulose membrane
(Whatman; Dassel, Germany) using a BioRad semidry transfer
apparatus at 100 V for 1 hour. Membranes were blocked in 5%
dry milk in TBST (Tris-buffered saline +0.1% Tween), and then
incubated over night at 4uC with appropriate primary antibody in
TBST at 1:1,000. The membranes were then washed 3x in TBST
before incubation for 1 hour at room temperature with peroxi-
dase-conjugated secondary antibodies in TBST at 1:10,000
(Perbio Science; Cramlington, UK). Antibody binding was
detected using an enhanced chemiluminescence HRP substrate
detection kit (Millipore; Watford, UK). Imaging and band
quantification were carried out using a Chemi Genius Bioimaging
Gel Doc System (Syngene; Cambridge, UK).
Electroporation
Electroporation was carried out using an ECM 830 Square
Wave Electroporation System (Harvard Apparatus, Holliston,
MA). Briefly, 6 ml of control or experimental plasmid DNA
dissolved in sterile PBS at a concentration of 2.5 mg/ml was
injected at the proximal and distal ends of the surgically exposed
tibialis muscle (TA). The control DNA, pDsRed2-C1 (Clontech,
Mountain View, CA), contained the dsRed cDNA driven by the
cytomegalovirus (CMV) promoter. The experimental DNA
contained the 2.39 kB of human Notch-1 generously donated by
Professor Tom Kadesch, University of Pennsylvania School of
Medicine, which comprises the intracellular (transcriptionally
active) domain of the protein driven by the CMV promoter
[24]. Both right and left legs were electroporated and the order of
the injections was randomized. Following injection, the muscles
were electroporated with 8620 ms pulses at 160 V/cm. The skin
was closed, the animals were given an analgesic injection of
buprenex (buprenorphine hydrochloride) and allowed to recover.
Figure 5. TGFb/Smad transcriptional inhibitors following acute resistance exercise. The levels of the Smad inhibitors SKI and active Notch
were determined at the end of a 20 min bout of high force lengthening contractions and then 0.5, 3, 6, 18, and 48 hours later. SKI and Notch protein
was normalized to GAPDH. GAPDH levels were unchanged in the 48 hours after acute stimulation. *indicates significantly increased versus control
(n = 4, p,0.05).
doi:10.1371/journal.pone.0068743.g005
Mighty and Resistance Exercise
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One week following electroporation, muscles were removed,
frozen in liquid nitrogen and RNA was isolated as described
above and qPCR was performed using primers to human NICD
(to detect NICD expression from the injected plasmid), the
canonical Notch target Hes-1 (hairy and enhancer of split-1), and
Mighty.
Statistical Analysis
One-way analysis of variance ANOVA (BrightStat.com) and
Tukey honestly significant difference posthoc test were used to
determine differences in protein level/phosphorylation and
mRNA expression. Values are displayed as mean 6 SEM, with
statistical significance set at 0.05.
Results
Effect of Acute Resistance Exercise on Myostatin
Transcriptional Activity
The expression of the myostatin target Mighty was determined
immediately following, 0.5, 3, 6, 18, and 48 hours after resistance
exercise. From 6 to 48 hours following resistance exercise, Mighty
expression was increased (Figure 1), suggesting myostatin tran-
scriptional activity decreased in the active muscle following acute
resistance exercise. At 48 hours, the amount of Mighty decreased
towards baseline. We next decided to exploit the differential
growth response of the muscles stimulated with this model [25,26].
The muscles in the anterior compartment of the lower limb
contract eccentrically and grow to a greater extent than the
muscles in the posterior compartment allowing for comparisons to
be made between the differential growth response of a particular
muscle and the change in gene expression in that muscle.
Comparing the expression of Mighty in the different hindlimb
muscles at the 6-hour time point with previous data on the growth
of individual muscles over 6 weeks [12] revealed a strong
correlation (R2= 0.9996; Figure 2). The relationship between
Mighty expression and skeletal muscle hypertrophy suggests that
increasing Mighty mRNA (inhibiting myostatin transcriptional
activity) may be important in the acute hypertrophic process.
Effect of Acute Resistance Exercise on Canonical
Myostatin Signaling
Since Mighty expression is inversely related to myostatin/Smad
signaling [15], we next sought to determine whether changes in
myostatin and Smad phosphorlylation triggered the increase
Mighty transcription. The expression of myostatin and its inhibitor
follistatin were both increased following resistance exercise
(Figure 3) with follistatin significantly increased at 3 and 6 hours
(Control = 1.4618.6%; 3 h=201.5680.5%; and
6 h= 170.3630.1%) and myostatin increased at the 6 h time
point (Control = 28.161.99%; 6 h= 252.1621.8%). The expres-
sion of the ActRIIB gene remained unchanged throughout the
time course (Figure 3). Consistent with both myostatin and
follistatin increasing similarly following acute resistance exercise,
Smad2 phosphorylation did not change at any point after acute
resistance exercise (Figure 4).
Notch Activation and Myostatin Signaling
Since there was no relationship between myostatin, Smad2
phosphorylation, and myostatin transcriptional activity, we deter-
mined the levels of the transcriptional repressors SKI and
activated Notch. The levels of SKI protein were unchanged
throughout the 48 h following resistance exercise (Figure 5A).
However, immediately after resistance exercise we noted an
83611.2% increase in the amount of activated Notch (Figure 5B).
The activated Notch remained high for 6 hours (78.1616.6%)
before returning to control levels by 18 hours (Con-
trol = 1.061.7%; 18 h= 15613%).
NICD and Hes-1 and Mighty Expression
To determine whether increased active Notch associates with
increases in Mighty expression, control (dsRED, empty plamid) or
NICD (plasmid containing the human Notch-1 intracellular
domain cDNA) cDNA was electroporated into the tibialis anterior
muscle of wild type C57/Bl6 mice (Figure 6). One week following
injection, the whole muscle level of the human NICD increased
345653%. The canonical Notch target Hes-1 increased
94.467.32%. Mighty mRNA increased an equivalent amount
(63613.4%), indicating that overexpression of NICD increases
Notch target gene expression and Mighty mRNA.
Discussion
Following resistance exercise, there is a small but significant
increase in the expression of the myostatin target gene Mighty that
correlates with the increase in muscle mass following training. This
is the first time that a relationship between acute myostatin
signaling and skeletal muscle hypertrophy has been observed,
suggesting that inhibition of myostatin may play a role in load-
induced muscle hypertrophy. Since myostatin inhibits Mighty
expression, this suggests that myostatin transcriptional activity may
be diminished from 6–48 hours following resistance exercise. The
decrease in myostatin transcriptional activity was not correlated
with changes in myostatin or follistatin mRNA or Smad2
phosphorylation. Instead, this decrease in transcriptional activity
was related to an increase in the cleavage and activation of Notch,
which is known to interact with Smad2/3 [27]. Electroporating a
plasmid containin the human NICD cDNA into muscle resulted in
an increase in both the canonical Notch target Hes-1 and the
myostatin target Mighty, suggesting that resistance exercise results
in the cleavage and activation of Notch. Notch would then
translocate to the nucleus and decrease myostatin/Smad tran-
scriptional activity.
Figure 6. NICD (Notch Intracellular Domain) electroporation
increases canonical Notch signaling and Mighty expression.
The expression of the NICD, Hes-1, and Mighty was quantified one week
following electroporation of the human NICD into the tibialis anterior
muscle of mice. Expression of each gene was normalized to GAPDH.
GAPDH levels were unchanged following electroporation. *indicates
significantly increased versus control (n = 4, p,0.05).
doi:10.1371/journal.pone.0068743.g006
Mighty and Resistance Exercise
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Mighty was cloned in a subtractive hybridization screen
comparing myostatin knockout and wild type control mice [15].
The cloned gene was expressed during myoblast differentiation
and overexpression of Mighty promoted muscle cell differentia-
tion. When virally expressed in mdx muscle, Mighty increased
muscle fiber size and overall muscle mass, suggesting that Mighty
could potentially play a role in skeletal muscle hypertrophy [15].
Importantly, acute treatment of muscle cells with myostatin
decreased Mighty promoter activity in a dose-dependent manner
that was dependent on activation of Smad2, suggesting that
Mighty mRNA levels would be a good marker for the activity of
the myostatin pathway [15]. The current report is the first report
showing that Mighty levels are increased following acute resistance
exercise and the correlation between Mighty mRNA and
hypertrophy supports a role for this gene in muscle growth.
However, how Mighty affects muscle hypertrophy has yet to be
determined.
Even though a number of reports have shown that myostatin is
transcriptionally downregulated by acute resistance exercise in rats
[9,10], we observed an increase in myostatin mRNA within the
working muscle in the hours following acute resistance exercise.
Our finding is in contrast to the decrease in myostatin mRNA that
occurs with overload hypertrophy [28,29,30]. Furthermore, when
other researchers have measured myostatin mRNA in rats after
4 days of electrical stimulation, they noted a decrease [31]. One
possible explanation for these differences is that Garma and
colleagues quantified myostatin relative to 18S RNA and not
GAPDH as we did in this study. This is relevant since these same
authors measured a 30% increase in total RNA. Since ribosomal
RNA makes up ,80% of total RNA, 18S rRNA levels would
increase disproportionately, making myostatin mRNA appear to
go down. Interestingly, in spite of the rise in myostatin mRNA in
the current study, Smad2 phosphorylation was unchanged
following acute resistance exercise possibly due to an almost
identical increase in follistatin mRNA. This demonstrates the
complexity of myostatin signaling and shows that measuring the
mRNA, or even the protein levels, of a single component of the
myostatin pathway may not provide a reliable estimate of the
transcriptional activity of the pathway.
Carlson et al. [18] have demonstrated that Notch can directly
inhibit TGFb/Smad signaling in skeletal muscle cells. These
authors suggested that an imbalance between TGFb/Smad and
Notch signaling may underlie the inability of skeletal muscle to
regenerate in older animals and that this may lead to sarcopenia
[32]. Interestingly, both myostatin inhibition and increasing
Mighty induce satellite cell proliferation [16,33,34,35], suggesting
that the positive effects of TGFb inhibition are potentially
mediated through Mighty. However, even though Mighty may
play a role in the activation of satellite cells, whether this is the role
of Mighty following resistance exercise has yet to be determined.
Interestingly, the Notch family member DLK1 can induce skeletal
muscle hypertrophy [20] and testosterone increases active Notch
in old muscles as part of the hypertrophic response [32]. Since
satellite cell activation can be accelerated by testosterone [36] and
testosterone can activate Notch and inhibit TGF-b, [32,37], this
suggests that Notch/Mighty signaling is important in load-induced
skeletal muscle growth, possibly through the modulation of satellite
cell activation. Consistent with this hypothesis, we show here that
active Notch is increased immediately following resistance exercise
and remains elevated for at least 6 hours. This time course of
activation fits well with the increase in Mighty mRNA. Further-
more, electroporation of the NICD into skeletal muscle results in
an increase in Mighty gene expression suggesting that notch
cleavage and activation can block myostatin transcriptional
activity in vivo.
In summary, acute resistance exercise results in a decrease in the
transcriptional activity of myostatin and therefore an increase in
the expression of Mighty, a gene that is associated with increases in
skeletal muscle mass. The increase in Mighty expression following
resistance exercise correlates with muscle growth, but is not the
result of a decrease in canonical myostatin signaling. Instead, acute
resistance exercise results in an increase in active Notch, a known
inhibitor of TGFb/Smad transcription. Lastly, overexpression of
active Notch in skeletal muscle is associated with a down
regulation in myostatin transcriptional activity as estimated by
increased Mighty gene expression. These data indicate that
inhibition of myostatin transcriptional activity by Notch may be
important in load-induced skeletal muscle hypertrophy and
identify Mighty as a genetic readout of myostatin signaling.
.
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